Drs. Nicole Urban, Steve Collins, Mary L. (Nora) Disis, Charles Drescher and Beth Karlan serve on the Executive Committee, the decision-making body of the POCRC.  This interdisciplinary group of scientists represents all of the disciplines and projects that comprise the POCRC.  They share responsibility for ensuring that interactions within and between projects are productive and that resources are allocated appropriately to take maximum advantage of the most promising research opportunities.  The Executive Committee is also responsible for ensuring that cores meet the needs of projects without redundancy or conflict.  In addition they are responsible for overall scientific leadership, including Inter-SPORE communication, coordination and collaborations, and for coordination and integration of POCRC activities.

Chaired by Dr. Urban, the Scientific Program Committee includes Executive Committee members and all Project and Core leaders and co-leaders. This group is responsible for the ongoing review and evaluation of scientific progress and meets quarterly for this purpose.  This committee is critical because it is the forum for interdisciplinary discussion of the science among POCRC senior scientists.  Members hear progress reports from each of the research projects and developmental research studies.  These meetings are held around themes including Early Detection and Risk, Immunotherapy, and Molecular Signatures.   The Scientific Program Committee provides interdisciplinary feedback and guidance to project presenters.

Chaired by Dr. Nita Maihle, Professor of OB/GYN Pathology and Pharmacology, at the Yale School of Medicine, the Board represents a multidisciplinary group of distinguished experts in translational ovarian cancer research. The Board meets annually to conduct a critical review of the POCRC program in its entirety, and to provide suggestions, criticisms and comments on future research directions.  The annual meeting is attended by all POCRC co- project co-leaders sand core leaders.  Project and core progress and future directions are presented to the EAB along with developmental research and career development progress. EAB members include representation from other currently funded SPOREs, as well as senior leaders throughout the country. Current members include: Ed Partridge, MD (University of Alabama); Robert Ozols, MD (Fox Chase Cancer Center); Maurie Markman, MD (MD Anderson Medical Center); Stephen Howell, MD (University of CA, San Diego); Carl June, MD (University of Pennsylvania); and Gustavo Rodriguez, MD (Northwestern University).

The Internal Advisory (or Translational) Committee meets at least once a year and is co-chaired by Drs. Disis and Karlan.  Ad-hoc committee members from the leadership teams as well as senior leaders with specific expertise are invited to participate in these meetings, as appropriate. The Translational Committee fosters the identification of biological insights and ensures that they are applied appropriately.  For example, the discovery of genes is of little value for therapeutics until we can understand something about gene function.  Our early detection work and other POCRC research projects are generating a wealth of data.  It is necessary to synthesize this information and infer from it in order to generate hypotheses to be tested in future work.